Summary

Turkey Pharmaceutical Market is anticipated to witness the growth of steady CAGR in the forecast period, 2024-2028. Turkey has a universal public health insurance, the Social Security Institution (SSI), which provides all registered residents with free healthcare facilities across the country. According to the current health system in Turkey, the country has some of the lowest rates of nurses and physicians in the WHO European Region. Many deaths in Turkey are caused by non-communicable diseases, and the government is working to combat unhealthy behaviors by investing in public health. Additionally, air pollution is another major public health challenge faced in the country.
Increasing Disease Occurrence Rates among the Elderly
The growing elderly population in the country is rising at a higher rate compared to the past 5 years' demographics of the country. According to the Turkish Statistical Institute (TurkStat) statistics, in 2019, the elderly population made up around 9.1% of the total population in the country. Moreover, the elderly population is subjected to an increased disease prevalence of heart and circulatory diseases in the country.
Growing Prevalence of Chronic Diseases
Turkey has developed its centralized Health system (established in 2019), as the Ministry of Health is serving the public with implementers of health policies, workforce planning, the regulation of medicines, vaccines, cosmetics, and medical devices, along with health research and development. The increasing number of cases of chronic diseases such as cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases in the country is creating a huge demand for the pharmaceutical market in the forecast period. The growing prevalence of risk factors such as (tobacco use, harmful use of alcohol, unhealthy diet, and physical inactivity is causing a huge market demand for Turkey Pharmaceutical market. According to the WHO’s Prevention and Control of non-communicable diseases in Turkey, NCDs (Non-Communicable Diseases) are responsible for 87.5% of all deaths in the country.
Turkey has a lower regional HIV/AIDS incidence rate. Although, according to a report by Positive Living Association, the average HIV incidence cases have been reduced globally, the new incident cases have increased in Turkey from 0.7 per 100000 population in 2009 to 3.9 per 100000 population in 2019.
Increasing Demand for Antimicrobials, Along with the Growing Cases of Antimicrobial Resistance
According to the WHO report, Turkey has one of the highest rates of antimicrobial consumption in the WHO European Region, and rates of antimicrobial resistance are also higher than in western and northern Europe. Irrespective of the government regulations & recommendations, the country has observed an irrational use of antibiotics in the country, leading to the condition of antimicrobial resistance. Organization for Economic Co-operation and Development (OECD) exposes the overuse and misuse of antimicrobials in the veterinary, medical sector and agricultural sectors, including unprescribed antimicrobial prescription, insufficient hygiene in hospitals, over usage in the livestock sector, all leading to antimicrobial resistance. According to the Organization for Economic Co-operation and Development (OECD) statistics, Turkey is leading to be the first among 42 countries in antibiotic consumption, and it holds the second position in terms of antimicrobial resistance. The antimicrobial resistance is creating a high demand for the pharmaceutical market as the consequence caused by the antimicrobial resistance are further required to be treated by undergoing health treatments and requiring medicines thereby propelling the pharmaceutical market growth and at the same time attributing the market growth in the forecast period.
Increasing Air Pollution and Its Harmful Health Effects
With an Air Pollution Index (API) rating of 20.62 g/m3, Turkey ranked 43rd in the world in terms of air pollution in 2019, according to statistics provided by IQ Air. This was due to Turkey's newly developed infrastructure and growing urbanization. The increasing air pollution leads to an increase in various health issues majorly, including chronic obstructive pulmonary disease (COPD), covering respiratory illnesses such as bronchitis, asthma, emphysema, and pneumonia. Tiny particles cause conditions such as irritation of the eyes, throat, and mouth that might become apparent in the polluted regions giving rise to multiple health issues and allergies. Moreover, increasing air pollution causes an increase in ischemic heart illnesses, strokes, and cardiac disorders, which increases demand for pharmaceuticals and encourages market expansion in the coming years.
Market Segmentation
The Turkey Pharmaceutical Market is segmented into drug type, product type, application, distribution, region, and company. Based on drug type, the market is segmented into branded and generic drugs. Based on the product type, the market is fragmented into prescription drugs and over-the-counter drugs. Depending on the application, the market is further fragmented into cardiovascular, musculoskeletal, oncology, anti-infective, metabolic disorder, and others. And by distribution channel, the market is segmented into retail pharmacy, hospital pharmacy, and e-pharmacy.

Market Players
Takeda İlaç Sağlık Sanayi Ticaret Limited Şirketi, Abbvie Turkey, GlaxoSmithKline Turkey, Sanofi Turkey, Roche Pharmaceuticals, Pfizer Limited, Novartis Turkey, AstraZeneca Turkey, Bristol Myers Squibb Pharmaceuticals, and Abbott Laboratories are some of the leading players operating in the Turkey Pharmaceutical Market.
Report Scope:
In this report, the global Turkey Pharmaceutical Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
• Turkey Pharmaceutical Market, By Drug Type
o Generic Drugs
o Branded Drugs
• Turkey Pharmaceutical Market, By Product Type:
o Prescription Drugs
o Over-The-Counter Drugs
• Turkey Pharmaceutical Market, By Application
o Cardiovascular
o Musculoskeletal
o Oncology
o Anti-infective
o Metabolic Disorder
o Others
• Turkey Pharmaceutical Market, By Distribution Channel:
o Retail Pharmacy
o Hospital Pharmacy
o E-Pharmacy
• Turkey Pharmaceutical Market, By Region:
o Marmara Region
o Central Anatolia
o Eastern Anatolia Region
o South-Eastern Anatolia Region
o Aegean Region
o Mediterranean Region
o Black Sea Region
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Turkey Pharmaceutical Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents